Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection

A. J. Matas, P. F. Gores, S. L. Kelley, M. Bielefield-Skrokov, M. Kinaszczuk, R. W G Gruessner, J. S. Najarian

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


15-deoxyspergualin (DSG) is a novel immunosuppressant which has been shown to be effective in preventing and treating rejection in animal allo- and xenotransplant models. Preliminary clinical studies suggest that DSG is an effective antirejection agent. In our study, 4 patients with biopsy-proven rejection episodes that were resistant to steroid and antibody therapy were then treated with DSG. All 4 rejection episodes responded to DSG therapy and all 4 kidneys continue to function (follow-up 7-15 months). However, 2 patients had additional rejection episodes after DSG therapy. Side effects during DSG treatment were minimal; 1 patient, who had also had multiple courses of antibody, developed a lymphoproliferative tumor 2 months after DSG administration. We conclude that DSG is effective in treating refractory renal transplant rejection episodes. Additional studies are necessary to determine the ideal place for DSG in treating renal transplants recipients with rejection.

Original languageEnglish (US)
Pages (from-to)116-119
Number of pages4
JournalClinical Transplantation
Issue number2 I
StatePublished - 1994


  • 15-deoxyspergualin
  • Renal transplant rejection


Dive into the research topics of 'Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection'. Together they form a unique fingerprint.

Cite this